Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating RG6496 in Huntington's disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• RG6496

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Huntington's Disease | Phase 1 | Status: RECRUITING